Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: Comparison with peptide YY

European Journal of Gastroenterology and Hepatology

Volumn 17, Issue 2, 2005, Pages 207-212

  Schmidt, Peter Thelin ^a   Ljung, Tryggve ^a   Hartmann, Bolette ^a   Hare, Kristine J ^a   Holst, Jens J ^a   Hellström, Per M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Crohn's disease; Peptide hormones; Proglucagon; Ulcerative colitis

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GROWTH FACTOR; PEPTIDE YY;

ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; ENDOCRINE CELL; ENTERITIS; FOOD INTAKE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; ILEUM BIOPSY; INFLAMMATION; INTESTINE BIOPSY; INTESTINE CELL; INTESTINE EPITHELIUM; POSTPRANDIAL STATE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECTUM BIOPSY; REGULATORY MECHANISM; TISSUE LEVEL;

COLITIS, ULCERATIVE; COLON; CROHN DISEASE; GLUCAGON-LIKE PEPTIDE 2; GLUCAGON-LIKE PEPTIDES; HUMANS; ILEUM; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PEPTIDE YY; PEPTIDES; POSTPRANDIAL PERIOD; RADIOIMMUNOASSAY;

EID: 14844297738     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200502000-00012     Document Type: Article

References (21)

1. Hartmann B, Johnsen AH, Orskov C, Adelhorst K, Thim L, Holst JJ. Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides 2000; 21:73-80.
2. Holst JJ, Orskov C. Incretin hormones - an update. Scand J Clin Lab Invest 2001; 234 (suppl):75-85.
3. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci, USA 1996; 93:7911-7916.
4. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122:531-544.
5. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS, Mortensen PB. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2002; 47:370-376.
6. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120:806-815.
7. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89:1070-1077.
8. Wen J, Phillips SF, Sarr MG, Kost LJ, Holst JJ. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am J Physiol 1995; 269:G945-G952.
9. Schmidt PT, Hartmann B, Bregenholt S, Holst JJ, Claesson MH. Deficiency of the intestinal growth factor, glucagon-like peptide 2, in the colon of SCID mice with inflammatory bowel disease induced by transplantation of CD4+ T cells. Scand J Gastroenterol 2000; 35:522-527.
10. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999; 276:G79-G91.
11. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999; 277:E937-E947.
12. Alavi K, Schwartz MZ, Palazzo JP, Prasad R. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000; 35:847-851.
13. Xiao Q, Boushey RP, Cino M, Drucker DJ, Brubaker PL. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 2000; 278: R1057-R1063.
14. Adrian TE, Savage AP, Bacarese-Hamilton AJ, Wolfe K, Besterman HS, Bloom SR. Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 1986; 90:379-384.
15. Koch TR, Roddy DR, Carney JA, Go VL. Peptide YY concentrations in normal ileum and colon and in idiopathic inflammatory bowel disease. Dig Dis Sci 1988; 33:1322-1328.
16. Tari A, Teshima H, Sumii K, Haruma K, Ohgoshi H, Yoshihara M, et al. Peptide YY abnormalities in patients with ulcerative colitis. Jpn J Med 1988; 27: 49-55.
17. El Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997; 242:413-419.
18. Holst JJ, Bersani M. Assay for peptide products of somatostatin gene expression. In: Conn PM (editor): Neuropeptide Technology. San Diego: Academic Press; 1991, pp. 3-22.
19. Ekman R, Wahlestedt C, Bottcher G, Sundler F, Hakanson R, Panula P. Peptide YY-like immunoreactivity in the central nervous system of the rat. Regul Pept 1986; 16:157-168.
20. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114:189-196.
21. Holst JJ. Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10:229-235.